文献速递泌尿生殖MR

圆桌讨论:反对使用多参数前列腺MRI方案的论据

Round table: arguments against using multiparametric prostate MRI protocols.
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

本文是四篇系列文章中反对使用多参数前列腺MRI(mpMRI)的一篇,讨论近期数据显示双参数MRI(bpMRI)与mpMRI在前列腺癌检测中表现相当,并回顾PI-RADS v2.1中动态对比增强的有限效用,最后详述使用对比剂带来的经济与时间成本、法律与后勤问题及潜在患者伤害。

要点

  • 近期数据显示bpMRI与mpMRI在前列腺癌检测中表现相当。
  • PI-RADS v2.1强调多数临床场景仍首选mpMRI而非bpMRI。
  • 使用对比剂涉及较大的经济与时间成本、法律与后勤问题及潜在患者伤害。

核心结论

  • 近期数据显示bpMRI与mpMRI在前列腺癌检测中表现相当。
  • 根据PI-RADS v2.1文件,动态对比增强在前列腺癌评估中的效用有限。
  • 使用对比剂涉及较大的经济与时间成本、法律与后勤问题及潜在患者伤害,须加以考虑。

研究设计与样本

  • 本文为四篇系列文章之一,提供反对使用mpMRI的论据。
  • bpMRI仅使用T2加权成像和扩散加权成像,在 prostate cancer 检测中持续获得支持。

诊断标准与关键数值

  • PI-RADS v2.1(2019年发布)强调多数临床场景仍首选mpMRI而非bpMRI。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Biparametric MRI (bpMRI), which uses only T2-weighted imaging and diffusion-weighted imaging, continues to gain support for the detection of prostate cancer, as this imaging technique offers many benefits over traditional mpMRI. However, the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 document released in 2019 emphasized that mpMRI is still preferred over bpMRI in most clinical scenarios. As one article in a series of four providing arguments for and against using mpMRI and bpMRI protocols, this paper provides arguments against using mpMRI. Within this article, we discuss recent data suggesting equivalent performance between bpMRI and mpMRI in the detection of prostate cancer. The limited utility of dynamic contrast enhancement in the evaluation of prostate cancer according to the PI-RADS v2.1 document is also reviewed. Finally, we detail the large financial and time costs, legal and logistical issues, and potential for patient harm that must be considered with the administration of contrast.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Ward R, Purysko AS. Round table: arguments against using multiparametric prostate MRI protocols. Abdom Radiol (NY). 2020. PMID: 32140766. doi:10.1007/s00261-020-02456-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。